Bergers Disease

Educational clinical summary of Bergers Disease for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This information is a clinical reference modeled after authoritative medical resources. It is intended for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Clinical judgment, based on the specific patient presentation and local guidelines, must always supersede generalized recommendations. Dosages and treatment protocols are subject to change and should be verified with current prescribing information.

Overview

Definition

IgA Nephropathy (IgAN), also known as Berger's Disease, is the most common form of primary glomerulonephritis worldwide. It is characterized by the predominant deposition of immunoglobulin A (IgA)—specifically IgA1 in its aberrantly glycosylated form—in the mesangium of the renal glomeruli. This deposition triggers a proliferation of mesangial cells and an inflammatory cascade, ultimately leading to glomerulosclerosis and chronic kidney disease (CKD).

Epidemiology

Prevalence: Most common primary glomerulonephritis globally, contributing to 2–5% of all end-stage renal disease (ESRD). Highly prevalent in Asian and Caucasian populations, particularly in southern Europe.
Incidence: Varies widely, ranging from 1.5 to 4.0 cases per 100,000 population per year.
Demographics: Typically diagnosed in adolescents and young adults (second to third decades of life), with a peak incidence between 15 and 30 years.
Sex: Male predominance (M:F ratio often 2:1 or higher).

Classification

IgAN is primarily classified pathologically using the Oxford Classification (MEST-C) system, which correlates histological findings with clinical outcomes:

Component	Definition	Prognostic Significance (Risk of ESRD/CKD progression)
M (Mesangial Hypercellularity)	M0 (<50% of glomeruli) or M1 (≥50% of glomeruli)	M1 independently predicts a worse renal outcome.
E (Endocapillary Hypercellularity)	E0 (Absent) or E1 (Present)	E1 independently predicts a worse renal outcome, especially in acute presentations.
S (Segmental Glomerulosclerosis)	S0 (Absent) or S1 (Present)	S1 independently predicts a worse renal outcome.
T (Interstitial Fibrosis/Tubular Atrophy)	T0 (<25%), T1 (25–50%), T2 (>50%)	T1 and T2 strongly predict CKD progression and ESRD.
C (Cellular/Fibrocellular Crescents)	C0 (Absent), C1 (Few, <25%), C2 (Many, >25%)	C1 and C2 indicate rapid progression; C2 has the worst prognosis.

Pathophysiology

Mechanism

The fundamental pathogenesis involves a multi-hit process leading to mesangial IgA deposition: 1. Hit 1 (Genetic Predisposition): IgAN is often polygenic, involving loci related to immune function (e.g., HLA region, genes related to complement factors). 2. Hit 2 (Abnormal IgA1): Production of aberrantly glycosylated IgA1 (Galactose-deficient IgA1, Gd-IgA1). Reduced galactose content in the hinge region exposes novel epitopes. This is central to the disease. 3. Hit 3 (Autoantibody Formation): The immune system recognizes Gd-IgA1 as foreign, leading to the formation of autoantibodies (IgG and IgA) that bind to Gd-IgA1, forming circulating immune complexes (CICs). 4. Hit 4 (Glomerular Targeting): These pathogenic CICs deposit in the glomerular mesangium due to their size and altered charge. 5. Inflammation and Damage: Mesangial cells recognize the deposited IgA complexes, proliferate, and release inflammatory mediators (cytokines, chemokines), leading to complement activation (predominantly the alternative and lectin pathways), resulting in ongoing inflammation, matrix expansion, glomerulosclerosis, and nephron loss.

Risk Factors

Genetic Factors: Family history of IgAN, specific HLA haplotypes.
Ethnicity: Asian (especially Chinese/Japanese) and Southern European descent.
Environmental Triggers: Recurrent mucosal infections (e.g., upper respiratory infections, gastroenteritis) often precede episodes of gross hematuria.

Protective Factors

Currently, no specific protective factors are definitively established. Management focuses on mitigating risk factors for progression (e.g., achieving strict blood pressure control, reducing proteinuria).

Clinical Presentation

Signs and Symptoms

Cardinal Features

Microscopic Hematuria: The most common finding (often persistent and asymptomatic) identified on routine urinalysis.
Gross Hematuria: Found in 40–50% of patients, typically synpharyngitic (occurring concurrently with or within 1–2 days of an upper respiratory or gastrointestinal mucosal infection). This presentation often differentiates it from post-infectious glomerulonephritis (which typically follows infection by 7–14 days).
Proteinuria: Variable, ranging from minimal (< 0.5 g/day) to nephrotic range (> 3.5 g/day).

Early Signs

Asymptomatic hematuria discovered incidentally.
Mild hypertension.

Advanced Signs

Nephrotic Syndrome: Severe proteinuria, generalized edema, hypoalbuminemia.
Hypertension (moderate to severe): Difficult to control, indicating established CKD.
Symptoms of CKD: Fatigue, decreased appetite, uremic symptoms.

Atypical Presentations

Rapidly Progressive Glomerulonephritis (RPGN): Characterized by acute, rapid decline in GFR over weeks to months, often due to extensive crescent formation (Oxford C2 classification). Requires urgent immunosuppression.
Systemic Vasculitis: IgAN may rarely overlap with Henoch-Schönlein Purpura (HSP) – now termed IgA vasculitis (IgAV), which presents with purpura, arthritis, and GI involvement.

Physical Examination

Inspection

General: Evidence of edema (periorbital, peripheral) if nephrotic syndrome is present.
Skin: Possible palpable purpura if associated with IgA vasculitis (IgAV).

Palpation

Blood Pressure: Assessment for hypertension is crucial.

Special Tests

Fundoscopy: May show hypertensive retinopathy changes in severe/longstanding hypertension.

Diagnostic Approach

History Taking

Key Questions

Hematuria Characteristics: Gross vs. microscopic, timing relative to illness (synpharyngitic presentation).
Infections: Recent history of upper respiratory or gastrointestinal illness.
Symptoms of Nephrotic Syndrome: Peripheral edema, frothy urine (proteinuria).
Blood Pressure History: Known hypertension and control status.
Family History: History of renal disease, especially in young relatives.

Red Flags (Indicating Potential RPGN or Urgent Evaluation)

Acute and rapid decline in urine output.
Rapid, significant rise in serum creatinine (e.g., doubling within 3 months).
Signs of volume overload or flash pulmonary edema.

Laboratory Tests

First-Line

Urinalysis with Microscopy: Essential for documenting hematuria (dysmorphic red blood cells, RBC casts) and proteinuria.
24-Hour Urine Collection or Urine Protein-to-Creatinine Ratio (UPCR): Quantifies proteinuria. UPCR > 0.5–1.0 g/g indicates high risk of progression.
Serum Creatinine and Estimated GFR (eGFR): Assess baseline kidney function.
Complete Metabolic Panel (CMP): Electrolytes, albumin (assess for nephrotic range).
Serology: Screen for secondary causes mimicking IgAN:
- Hepatitis B and C, HIV (to rule out secondary IgAN).
- ANA (to rule out SLE).
- ANCA (to rule out pauci-immune GN).
- Complement levels (C3, C4—typically normal in primary IgAN, low in post-infectious GN or SLE).

Confirmatory (Gold Standard)

Renal Biopsy: Required for definitive diagnosis and prognosis. Biopsy findings must demonstrate dominant mesangial IgA deposition by immunofluorescence, along with characteristic light and electron microscopy findings (mesangial proliferation and expansion). The Oxford MEST-C score must be assigned.

Monitoring

eGFR and Serum Creatinine: Every 3–6 months based on stability.
UPCR or 24h Protein: Every 3–6 months to monitor response to therapy.
Blood Pressure: Monthly until strict targets are met.

Imaging

Advanced

Generally not required unless an associated systemic vasculitis or other secondary cause (e.g., malignancy) is suspected.

Management

The cornerstone of IgAN management is strict blood pressure control and reduction of proteinuria through optimization of the renin-angiotensin-aldosterone system (RAAS) blockade.

Acute Management

Immediate

If presenting with severe acute kidney injury or RPGN (creatinine rising rapidly, extensive crescents (C2) on biopsy):
- High-dose corticosteroids (e.g., Methylprednisolone 0.5–1 g IV daily for 3 days).
- Consider adding cyclophosphamide or other immunosuppressants (as per chronic management for RPGN).

Stabilization

Initiate or optimize RAAS blockade (ACEi/ARB).
Aggressive blood pressure control.
Management of volume overload (diuretics) or electrolyte abnormalities.

Chronic Management

Pharmacological (Based on KDIGO 2021 Guidelines)

Indication	First-Line Agents (Renoprotection)	Target/Dosage	Notes
Proteinuria ($\geq 0.5$ g/day) and Hypertension	ACE Inhibitors (ACEi) or Angiotensin Receptor Blockers (ARBs)	Target BP: < 120/80 mmHg (AHA/ACC target for CKD); Dosage titrated to maximum tolerated dose.	Essential first-line therapy, even in normotensive patients with proteinuria $\geq 0.5$ g/day.
High-Risk Progressive IgAN (Proteinuria persistent $\geq 0.75-1.0$ g/day despite 3-6 months of optimized supportive care)	Glucocorticoids (Corticosteroids)	Prednisone 0.5 mg/kg/day (max 40-60 mg) for 2 months, followed by slow taper over 6 months OR Budesonide (Targeted-release/Enteric-coated) 16 mg PO daily for 9 months.	Systemic steroids carry significant side effects. Budesonide targets the gut mucosal immune system and has shown efficacy in reducing proteinuria with fewer systemic side effects.
Severe/RPGN (eGFR rapidly declining, active inflammation, crescents $\geq 50\%$)	Intravenous High-Dose Corticosteroids + Cyclophosphamide (or similar potent regimen)	Based on established RPGN protocols.	Treatment is similar to other forms of crescentic GN; followed by maintenance with azathioprine/mycophenolate.

Non-pharmacological

Dietary Salt Restriction: Highly effective for BP control and enhancing RAAS blockade efficacy (Target: $< 2$ g sodium/day).
Fluid Management: Maintain euvolemia.
Protein Restriction: Moderate protein intake (e.g., $\leq 0.8$ g/kg/day) for patients with advanced CKD.

Treatment Algorithms

First-Line (All IgAN Patients)

Supportive Care: Optimized blood pressure control (target < 120/80 mmHg).
RAAS Blockade: High-dose ACEi or ARB, titrated to maximally tolerated dose, aiming for proteinuria reduction $\geq 50\%$.
Duration: Maintain optimized supportive care for 3–6 months.

Second-Line (Persistent Proteinuria)

If UPCR remains $\mathbf{\geq 0.75-1.0}$ g/g despite optimal supportive care (RAAS blockade):
- Consider a 6–9 month course of systemic corticosteroids or targeted-release budesonide (especially if eGFR $\mathbf{> 50}$ mL/min/1.73m$^2$).
- Note: Immunosuppression is generally not recommended for patients with eGFR $\mathbf{< 30}$ mL/min/1.73m$^2$ due to poor benefit-to-risk ratio.

Refractory Cases

If proteinuria remains high despite supportive care and steroids:
- Mycophenolate Mofetil (MMF): Less definitive evidence than steroids, but may be used in certain ethnic groups (e.g., Asian populations in some studies) or as maintenance following RPGN therapy.
- Rituximab: Limited evidence for primary IgAN, reserved for highly refractory or rapidly worsening cases, often used off-label.
- Tonsillectomy: Controversial, but some data support benefit in reducing episodes of gross hematuria and potentially slowing progression in Asian populations, particularly when frequent synpharyngitic episodes occur.

Complications

Common

Hypertension (often complicates and accelerates progression).
Chronic Kidney Disease (CKD).
Nephrotic Syndrome (increased risk of thrombosis and infection).

Serious

Rapidly Progressive Glomerulonephritis (RPGN): Rapid loss of kidney function requiring urgent immunosuppression and potentially dialysis.
Thromboembolism: Risk increased with nephrotic-range proteinuria.

Long-term

End-Stage Renal Disease (ESRD): Approximately 25–40% of patients progress to ESRD within 20 years of diagnosis.
Cardiovascular Disease (secondary to CKD and chronic inflammation).

Prognosis

Factors Affecting Outcome (Poor Prognostic Indicators)

Proteinuria: Persistent proteinuria $>\mathbf{1.0}$ g/day is the single strongest indicator of progression.
Hypertension (uncontrolled).
Reduced GFR at Presentation: Baseline eGFR $<\mathbf{60}$ mL/min/1.73m$^2$.
Histopathology (Oxford Classification): High T (Interstitial Fibrosis/Tubular Atrophy) and C (Crescents) scores are associated with worse prognosis.
Older Age at onset.

Survival

Overall 10-year kidney survival (freedom from ESRD) is approximately 80–90%; 20-year survival drops to 60–75%.
Once ESRD occurs, treatment is renal replacement therapy (dialysis or transplantation). IgAN can recur in 30–50% of kidney transplants.

Quality of Life

Initially good, but declines with the progressive development of CKD, related symptoms, and the need for dietary restrictions and frequent medical visits.

Prevention

Primary

No current strategies exist to prevent the initial production of Gd-IgA1 or the development of IgAN. Research focuses on modulating mucosal immunity and IgA glycosylation.

Secondary

Early Diagnosis: Screening high-risk individuals (e.g., those with a family history) for microscopic hematuria and proteinuria.
Aggressive Supportive Care: Prompt initiation and maximization of RAAS blockade and BP control upon diagnosis to slow progression.

Tertiary

Complication Management: Aggressive management of hypertension, dyslipidemia, and anemia associated with CKD to prevent cardiovascular or renal events.

Special Populations

Pediatric

Presentation: Often presents with gross hematuria and synpharyngitic recurrence. Nephrotic syndrome is less common than in adults.
Management: Supportive care (RAAS blockade) is the mainstay. Immunosuppression is generally reserved for nephrotic syndrome or RPGN only.

Geriatric

Presentation: Often present later with established CKD, less commonly with gross hematuria.
Management: Increased caution with aggressive immunosuppression due to higher infection risks. Focus heavily on cardiovascular and BP management.

Pregnancy

Risk: Pregnancy increases the risk of preeclampsia and an accelerated decline in GFR, particularly if baseline proteinuria $\mathbf{> 1.0}$ g/day or baseline CKD (eGFR $<\mathbf{60}$) is present.
Medications: ACEi/ARBs are contraindicated in pregnancy (teratogenic). They must be switched to safer anti-hypertensive agents (e.g., Labetalol, Nifedipine, Methyldopa).

Comorbidities

Diabetes and Hypertension: Control of blood glucose and optimization of blood pressure are critical, often requiring combined ACEi/ARB and non-RAAS agents (e.g., calcium channel blockers). SGLT2 inhibitors are now recommended for patients with CKD $\geq$ stage 2 and albuminuria (UPCR $\geq 200–300$ mg/g) to provide additional renoprotection.

Clinical Pearls

Diagnostic

Timing of Hematuria: Think IgAN when hematuria occurs with the concurrent URTI (synpharyngitic); think post-infectious GN when hematuria occurs $\mathbf{1-3}$ weeks after the URTI.
C3/C4: In contrast to lupus nephritis and post-infectious GN, complement levels (C3/C4) are typically normal in primary IgAN.

Treatment

RAAS Blockade is Non-Negotiable: Must be maximized, regardless of blood pressure status, if proteinuria is present.
Steroid Indication: Do not initiate systemic steroids unless the patient has been on maximized supportive care for 3–6 months without meeting proteinuria targets, and eGFR remains $>30-50$ mL/min.

Pitfalls

Stopping RAAS Blockade: Discontinuing ACEi/ARB prematurely due to fear of minor creatinine bumps can accelerate renal decline. Small increases in creatinine (up to $\approx 30\%$) are expected and acceptable if hyperkalemia is controlled.
Underestimating Proteinuria: Failure to recognize proteinuria $>1.0$ g/day as a high-risk factor leading to delayed initiation of intensive therapy.

Recent Updates

Guidelines (KDIGO 2021 Update)

BP Target: Relaxed from $< 130/80$ to the standard CKD target of $< 120/80$ mmHg (when feasible and measured accurately), based on general CKD evidence.
SGLT2 Inhibitors: Strongly recommended for patients with CKD (eGFR $\geq 20$ mL/min) and albuminuria, including those with IgAN, for their cardiorenal protective effects.
Targeted-Release Budesonide (TR-Budesonide): Has emerged as a kidney-sparing steroid approach for high-risk patients (persistent proteinuria $>\mathbf{1.0}$ g/day) based on Phase 3 trials (e.g., NefIgArd trial).

Evidence

Complement Inhibition: Ongoing trials are investigating novel therapies targeting the complement cascade (e.g., C3 inhibitors, factor B inhibitors) due to the role of the alternative and lectin pathways in IgAN pathogenesis.
B-cell Depletion: Studies suggest rituximab may be beneficial in some non-responders, especially those with features of minimal change disease or rapid decline, but is not standard first-line.

Controversies

Optimal Duration and Dose of Steroids: Debate remains regarding the optimal systemic steroid sparing regimens vs. targeted delivery (e.g., TR-Budesonide).
Role of Tonsillectomy: Strong belief in its benefit in some East Asian centers vs. limited acceptance in most Western guidelines.

Key References

Guidelines: Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.
Studies:
- STOP-IgAN Trial: Demonstrated that immunosuppression added little benefit to optimized supportive care in patients with non-severe IgAN.
- NefIgArd Trial: Supported the use of Targeted-Release Budesonide in reducing proteinuria and stabilizing GFR in high-risk IgAN patients.
Reviews: UpToDate; various comprehensive reviews on IgA nephropathy risk stratification and novel therapeutic targets.